Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

The lawsuit involves the "off-label" uses of the anti-psychotic drug Zyprexa, the Jackson (Miss.) Clarion Ledger reported.

The suit alleges representatives of Eli Lilly persuaded Mississippi doctors to prescribe the drug to patients suffering from conditions such as anxiety, mood swings and disturbed sleep when the drug is only approved to treat bipolar disorder and schizophrenia.

Tim Balducci, Mississippi special assistant attorney general, told the Clarion Ledger Eli Lilly targeted Mississippi because the state's Medicaid system cannot determine when a medication is prescribed for non-approved uses.

The Indianapolis-based Eli Lilly has 30 days to respond to the suit.

Copyright 2006 by United Press International

Explore further: Guinea president declares 45-day Ebola 'emergency' in five regions

add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Recommended for you

Third Minnesota turkey farm hit by bird flu outbreak

14 hours ago

An outbreak of a bird flu strain that's deadly to poultry deepened Saturday when state and federal officials confirmed a third Minnesota turkey farm has been infected, this time in one of the state's top poultry producing ...

New way to evaluate meniscus tear outcomes

20 hours ago

An individual's meniscus (cushion in the knee) is one of the most important ligaments in the leg providing stability, load bearing and preservation of the knee joint. It is also one of the most easily injured areas and difficult ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.